Bristol Myers Squibb Ireland Unlimited competitive analysis

Latest publications and patents of Bristol Myers Squibb Ireland Unlimited New

Explore the latest publications and patents granted to Bristol Myers Squibb Ireland Unlimited, showcasing their recent innovations and technological advancements.

Last updated on: Sep 28, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Bristol Myers Squibb Ireland Unlimited

Nov 13, 2019Apixaban FormulationsRevoked
Oct 16, 2019Apixaban FormulationsRevoked
Oct 16, 2019Apixaban FormulationsRevoked
Dec 5, 2018Apixaban FormulationsRevoked
Jul 25, 2018Hiv Treatment Formulation Of Atazanavir And CobicistatGranted And Under Opposition

Explore Bristol Myers Squibb Ireland Unlimited's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 13, 2019Apixaban Formulations12
Oct 16, 2019Apixaban Formulations10
Oct 16, 2019Apixaban Formulations10
Dec 5, 2018Apixaban Formulations9
Jul 25, 2018Hiv Treatment Formulation Of Atazanavir And Cobicistat1

Latest PTAB cases involving Bristol Myers Squibb Ireland Unlimited

Discover the latest PTAB cases involving Bristol Myers Squibb Ireland Unlimited, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Bristol Myers Squibb Ireland Unlimited with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 42 - - Non-Active
GENERICS UK212 - - - Highly Aggressive
INTAS PHARMACEUTICALS1643 - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive